A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- 16 Apr 2018 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 16 Apr 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
- 24 Jun 2016 Status changed from not yet recruiting to recruiting.